Vitura Health (ASX:VIT) - Cotización, noticias y análisis

Resumen de acción VIT

Vitura Health Limited se dedica a la venta y distribución de productos de cannabis medicinal en Australia y Asia.

VIT fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	4/6

Recompensas

Cotiza un 61.4% por debajo de nuestra estimación de su valor justo

Análisis de riesgos

Alta volatilidad del precio de la acción en los últimos 3 meses

Historial de dividendos inestable

Los accionistas han sido diluidos en el último año

No tiene una capitalización de mercado significativa (A$60M)

Competidores de Vitura Health Limited

Vita Life Sciences

ASX:VLS

AU$119.8m

Probiotec

ASX:PBP

AU$231.0m

ECS Botanics Holdings

ASX:ECS

AU$28.3m

Neuren Pharmaceuticals

ASX:NEU

AU$2.4b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Vitura Health
Historical stock prices
Current Share Price	AU$0.10
52 Week High	AU$0.60
52 Week Low	AU$0.092
Beta	0.16
1 Month Change	-43.24%
3 Month Change	-57.14%
1 Year Change	-67.69%
3 Year Change	0%
5 Year Change	n/a
Change since IPO	-69.12%

Noticias y actualizaciones recientes

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Apr 11

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Feb 27

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Feb 25

Recent updates

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Apr 11

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Feb 27

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Feb 25

Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)

Dec 13

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Nov 21

Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?

Nov 01

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Jul 18

Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%

Sep 12

If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity

Sep 05

Rentabilidad de los accionistas

	VIT	AU Pharmaceuticals	Mercado AU
7D	-38.2%	-2.6%	0.9%
1Y	-67.7%	29.2%	5.7%

Rentabilidad vs. Industria: VIT obtuvo unos resultados inferiores a los del sector Australian Pharmaceuticals , que el año pasado arrojó un rendimiento del 29.2%.

Rentabilidad vs. Mercado: VIT obtuvo unos resultados inferiores a los del mercado Australian, que fue del 5.7% el año pasado.

Volatilidad de los precios

Is VIT's price volatile compared to industry and market?
VIT volatility
VIT Average Weekly Movement	17.8%
Pharmaceuticals Industry Average Movement	10.7%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.5%

Precio estable de las acciones: El precio de las acciones de VIT ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de VIT(18%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Australian.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2018	n/a	Rodney Cocks	vitura.com.au

Vitura Health Limited se dedica a la venta y distribución de productos de cannabis medicinal en Australia y Asia. La empresa gestiona CanView, una plataforma en línea que ofrece soluciones de prescripción, dispensación y gestión de medicación para cannabis medicinal; CDA Clinics, que ofrece consultas sobre cannabis medicinal y servicios de prescripción; y Cannadoc, una clínica de cannabis medicinal que ofrece consultas de telesalud. También ofrece psicodélicos bajo la marca Cortexa; y medicamentos basados en plantas, como aceite de triglicéridos de cadena media y productos de flor entera bajo la marca Adaya.

Resumen de fundamentos de Vitura Health Limited

¿Cómo se comparan los beneficios e ingresos de Vitura Health con su capitalización de mercado?
Estadísticas fundamentales de VIT
Capitalización bursátil	AU$60.47m
Beneficios(TTM)	AU$9.40m
Ingresos (TTM)	AU$119.66m

6.4x

Ratio precio-beneficio (PE)

0.5x

Ratio precio-ventas (PS)

¿Está VIT sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de VIT
Ingresos	AU$119.66m
Coste de los ingresos	AU$81.81m
Beneficio bruto	AU$37.85m
Otros gastos	AU$28.45m
Beneficios	AU$9.40m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.016
Margen bruto	31.63%
Margen de beneficio neto	7.86%
Ratio deuda/patrimonio	15.9%

¿Cómo se ha desempeñado VIT a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

9.5%

Rentabilidad actual por dividendo

60%

Ratio de pagos

Resumen de acción VIT

Recompensas

Análisis de riesgos

Competidores de Vitura Health Limited

ASX:VLS

AU$119.8m

ASX:PBP

AU$231.0m

ASX:ECS

AU$28.3m

ASX:NEU

AU$2.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New major risk - Share price stability

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

First half 2024 earnings released: EPS: AU$0.006 (vs AU$0.014 in 1H 2023)

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Now 39% undervalued after recent price drop

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Recent updates

New major risk - Share price stability

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

First half 2024 earnings released: EPS: AU$0.006 (vs AU$0.014 in 1H 2023)

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Now 39% undervalued after recent price drop

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)

Vitura Health Limited Receives Shareholder Requisition from Elizabeth Sarah Jansen

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?

Vitura Health Limited (ASX:VIT) completed the acquisition of acquire an unknown stake in Doctors on Demand from Yeates Ventures Pty Ltd and Kirsty Garrett.

New minor risk - Shareholder dilution

Vitura Health Limited, Annual General Meeting, Nov 28, 2023

Upcoming dividend of AU$0.01 per share at 2.7% yield

Vitura Health Limited Announces Dividend for the Year Ended 30 June 2023, Payable on or Around, 28 September 2023

New major risk - Earnings quality

New minor risk - Financial data availability

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Insider recently sold AU$2.3m worth of stock

New minor risk - Share price stability

Chief Commercial Officer recently sold AU$5.9m worth of stock

High number of new and inexperienced directors

Cronos Australia Limited Announces Changes to Clinical Operations

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Board Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Ceases of Benjamin D.N. Jansen as Chief Medical Officer

Cronos Australia Limited Provides Update on Canview 2.0 Platform

Cronos Australia Limited, Annual General Meeting, Nov 29, 2022

Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%

Cronos Australia Limited Appoints Jenelle Frewen and Simone Scovell as Independent Non-Executive Director

If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity

Cronos Australia Limited Announces Dividend for the Year Ended 30 June 2022, Dividend Payment Date Is 11 October 2022

Full year 2022 earnings released: EPS: AU$0.013 (vs AU$0.031 loss in FY 2021)

Cronos Australia Limited to Report Q2, 2022 Results on Jul 27, 2022

Cronos Australia Announces Resignation of Shane Tanner, Chairman and Director

Cronos Australia Limited Announces Resignation of Kurt Thomas Schmidt as Director

First half 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cronos Australia Limited (ASX:CAU) completed the acquisition of Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited (ASX:CAU) entered into Merger implementation agreement to acquire Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited Announces Launch of Additional Products in Key Asian Markets

Cronos Australia Limited Provides Revenue Guidance for the Fourth Quarter of 2021

Cronos Australia Limited Announces Launch of First Personal Care Brand in North Asian Markets with Bathing Shed

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Vitura Health Limited

6.4x

0.5x

Beneficios e Ingresos

Dividendos

9.5%

60%